| Literature DB >> 1627368 |
M A Richards1, P Hopwood, A J Ramirez, C J Twelves, J Ferguson, W M Gregory, R Swindell, W Scrivener, J Miller, A Howell.
Abstract
The influence of scheduling of doxorubicin on response, survival and quality of life was assessed in a randomised trial in patients with advanced breast cancer, none of whom had previously received cytotoxic chemotherapy for advanced disease. 28 patients received 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1) and 31 patients received 25 mg/m2 weekly for 12 courses (arm 2). Response rates and median time to progression were similar in the two arms and median survival was 8 months in both arms. However, amongst patients receiving treatment every 3 weeks, psychological distress measured using the Rotterdam symptom checklist fell significantly over the course; no such change was observed in those treated weekly. Physical symptoms related to cancer improved during treatment similarly for both groups.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1627368 DOI： 10.1016/0959-8049(92)90447-a
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162